haloperidol	B-Drug
;	O
      
While	O
the	O
effects	O
of	O
chronic	O
phenytoin	B-Drug
or	O
carbamazepine	B-Drug
therapy	O
on	O
the	O
action	O
of	O
MIVACRON	B-Brand
are	O
unknown	O
slightly	O
shorter	O
durations	O
of	O
neuromuscular	O
block	O
may	O
be	O
anticipated	O
and	O
infusion	O
rate	O
requirements	O
may	O
be	O
higher	O
.	O
      
Although	O
a	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
there	O
have	O
been	O
reports	O
of	O
bleeding	O
and	O
/	O
or	O
prolonged	O
prothrombin	O
time	O
in	O
patients	O
treated	O
with	O
TRENTAL	B-Brand
with	O
and	O
without	O
anticoagulants	B-Group
or	O
platelet	B-Group
aggregation	I-Group
inhibitors	I-Group
.	O
      
Increasing	O
the	O
indinavir	B-Drug
dose	O
to	O
9	O
mg	O
every	O
9	O
hours	O
does	O
not	O
compensate	O
for	O
the	O
increased	O
indinavir	B-Drug
metabolism	O
due	O
to	O
SUSTIVA	B-Brand
.	O
      
These	O
effects	O
were	O
not	O
considered	O
clinically	O
important	O
.	O
      

      
